Daphne Quimi Receives Stock Award at Amicus Therapeutics Inc (FOLD) — SEC Form 4, Jan 04, 2023

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Daphne Quimi

CFO

TXN 2023-01-03 · FILED 2023-01-04

Equity Position 394K sh 343,887 → 393,655

Equity Change +14.5% shares held after vs before

Filing Lag 1 business day within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Amicus Therapeutics Inc

FOLD CIK 0001178879

Reporting Owner

Name	Relationship
Daphne Quimi CIK 0001543031	CFO

Daphne Quimi at Amicus Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Amicus Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common Stock	2023-01-02	F - Tax Payment	15,165 D	$12.21	-$185,165	320,147	Direct
Common StockF1	2023-01-03	A - Award/Grant	73,508 A	$0.00	—	393,655	Direct
Common Stock	2023-01-03	F - Tax Payment	8,575 D	$11.93	-$102,300	385,080	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Options (right to buy)F2	$11.93	2023-01-03	A - Award/Grant	130,480 A	$0.00	2033-01-03	130,480 Common Stock	Direct

Footnotes (2)

F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2024 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Show more
F2: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 5 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Amicus Therapeutics Inc

GET /v1/forms/4/0001209191-23-001394 API docs